NCBiotech Company Directory is a comprehensive listing of North Carolina's life science industry New search

Enzyvant Inc.

Enzyvant develops therapeutics for treatment of rare diseases. Their focuses are RVT-802, an investigational tissue-based therapy for immune deficiency resulting from DiGeorge Anomaly, and RVT-801, an enzyme replacement therapy to treat Farber disease.

324 Blackwell St.
Durham, NC 27701
County 
Durham
Region 
Triangle

Company Details

Company type 
Bioscience Company
Year founded 
2016
Employment Range in NC 
20-49
US headquarters 
North Carolina
Global headquarters 
United States
Primary site activity 
Research and Development
All company activities 
Research and Development
Products under development 
RVT-802, an investigational tissue-based therapy for the treatment of primary immunodeficiency associated with complete DiGeorge Anomaly and RVT-801, a recombinant form of rhAC for use as an enzyme replacement therapy to treat Farber disease.